Systemic Amyloidosis Market Insights Video

According to Cognitive Market Research, the global systemic amyloidosis market size was USD 4256.5 million in 2024. It will expand at a compound annual growth rate (CAGR) of 6.00% from 2024 to 2031.

• North America held the major market share for more than 40% of the global revenue with a market size of USD 1702.60 million in 2024 and will grow at a compound annual growth rate (CAGR) of 4.2% from 2024 to 2031.
• Europe accounted for a market share of over 30% of the global revenue with a market size of USD 1276.95 million.
• Asia Pacific held a market share of around 23% of the global revenue with a market size of USD 979.00 million in 2024 and will grow at a compound annual growth rate (CAGR) of 8.0% from 2024 to 2031.
• Latin America had a market share of more than 5% of the global revenue with a market size of USD 212.83 million in 2024 and will grow at a compound annual growth rate (CAGR) of 5.4% from 2024 to 2031.
• Middle East and Africa had a market share of around 2% of the global revenue and was estimated at a market size of USD 85.13 million in 2024 and will grow at a compound annual growth rate (CAGR) of 5.7% from 2024 to 2031.
• The primary systemic amyloidosis (PSA) category held the highest systemic amyloidosis market revenue share in 2024.